Immunic Analyst Ratings
Immunic Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/10/2023 | 278.38% | Wedbush | $5 → $7 | Maintains | Outperform |
| 07/27/2023 | 170.27% | Wedbush | → $5 | Reiterates | Outperform → Outperform |
| 01/31/2023 | 170.27% | Wedbush | → $5 | Assumes | → Outperform |
| 10/21/2022 | 170.27% | SVB Leerink | $9 → $5 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1305.41% | HC Wainwright & Co. | → $26 | Assumes | → Buy |
| 08/08/2022 | 1791.89% | Aegis Capital | $40 → $35 | Maintains | Buy |
| 06/03/2022 | 386.49% | SVB Leerink | $45 → $9 | Maintains | Outperform |
| 05/18/2022 | 2008.11% | Piper Sandler | $71 → $39 | Maintains | Overweight |
| 09/07/2021 | 1251.35% | HC Wainwright & Co. | $40 → $25 | Maintains | Buy |
| 04/15/2021 | 2872.97% | Aegis Capital | → $55 | Initiates Coverage On | → Buy |
| 03/24/2021 | 2872.97% | JMP Securities | → $55 | Initiates Coverage On | → Market Outperform |
| 10/02/2020 | 2332.43% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 08/26/2020 | 3737.84% | Piper Sandler | → $71 | Initiates Coverage On | → Overweight |
| 08/21/2020 | 2927.03% | HC Wainwright & Co. | $60 → $56 | Maintains | Buy |
| 08/03/2020 | 3143.24% | HC Wainwright & Co. | $45 → $60 | Maintains | Buy |
| 07/20/2020 | 2062.16% | BMO Capital | → $40 | Initiates Coverage On | → Outperform |
| 06/05/2020 | 3089.19% | Wedbush | → $59 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 2332.43% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
| 08/12/2019 | 2062.16% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 07/11/2019 | 2062.16% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月10日 | 278.38% | 韋德布什 | $5→$7 | 維護 | 跑贏大盤 |
| 07/27/2023 | 170.27% | 韋德布什 | →$5 | 重申 | 跑贏→跑贏大盤 |
| 2023年年1月31日 | 170.27% | 韋德布什 | →$5 | 假設 | →跑贏大盤 |
| 2022年10月21日 | 170.27% | SVB Leerink | $9→$5 | 評級下調 | 跑贏→市場表現 |
| 2022/09/19 | 1305.41% | HC Wainwright公司 | →$26 | 假設 | →購買 |
| 2022/08/08 | 1791.89% | 宙斯盾資本 | $40→$35 | 維護 | 買 |
| 06/03/2022 | 386.49% | SVB Leerink | $45→$9 | 維護 | 跑贏大盤 |
| 2022/05/18 | 2008.11% | 派珀·桑德勒 | $71→$39 | 維護 | 超重 |
| 09/07/2021 | 1251.35% | HC Wainwright公司 | $40→$25 | 維護 | 買 |
| 04/15/2021 | 2872.97% | 宙斯盾資本 | →$55 | 開始承保 | →購買 |
| 03/24/2021 | 2872.97% | JMP證券 | →$55 | 開始承保 | →市場跑贏大盤 |
| 10/02/2020 | 2332.43% | SVB Leerink | →$45 | 開始承保 | →跑贏大盤 |
| 2020/08/26 | 3737.84% | 派珀·桑德勒 | →$71 | 開始承保 | →超重 |
| 2020年08月21日 | 2927.03% | HC Wainwright公司 | $60→$56 | 維護 | 買 |
| 08/03/2020 | 3143.24% | HC Wainwright公司 | $45→$60 | 維護 | 買 |
| 07/20/2020 | 2062.16% | 蒙特利爾銀行資本 | →$40 | 開始承保 | →跑贏大盤 |
| 06/05/2020 | 3089.19% | 韋德布什 | →$59 | 開始承保 | →跑贏大盤 |
| 05/11/2020 | 2332.43% | HC Wainwright公司 | →$45 | 開始承保 | →購買 |
| 2019年08月12日 | 2062.16% | 查爾丹資本 | →$40 | 開始承保 | →購買 |
| 2019年07月11日 | 2062.16% | 查爾丹資本 | →$40 | 開始承保 | →購買 |
What is the target price for Immunic (IMUX)?
免疫系統(IMUX)的目標價格是多少？
The latest price target for Immunic (NASDAQ: IMUX) was reported by Wedbush on October 10, 2023. The analyst firm set a price target for $7.00 expecting IMUX to rise to within 12 months (a possible 278.38% upside). 4 analyst firms have reported ratings in the last year.
韋德布什於2023年10月10日報道了免疫(納斯達克：IMUX)的最新目標價。這家分析公司將目標價定為7美元，預計IMUX將在12個月內上漲至(可能上漲278.38%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Immunic (IMUX)?
免疫系統(IMUX)的最新分析師評級是多少？
The latest analyst rating for Immunic (NASDAQ: IMUX) was provided by Wedbush, and Immunic maintained their outperform rating.
免疫公司(納斯達克代碼：IMUX)的最新分析師評級由韋德布什提供，免疫公司維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
免疫(IMUX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與免疫的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。免疫的上一次評級是在2023年10月10日提交的，所以你應該預計下一次評級將在2024年10月10日左右的某個時候提供。
Is the Analyst Rating Immunic (IMUX) correct?
分析師評級免疫(IMUX)正確嗎？
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a maintained with a price target of $5.00 to $7.00. The current price Immunic (IMUX) is trading at is $1.85, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的免疫(IMUX)評級保持不變，目標價在5.00美元至7.00美元之間。免疫(IMUX)目前的交易價格為1.85美元，超出了分析師的預測區間。